|Bid||4.30 x 400|
|Ask||4.80 x 100|
|Day's range||4.62 - 4.79|
|52-week range||4.20 - 9.86|
|PE ratio (TTM)||N/A|
|Earnings date||7 Aug 2017 - 11 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.83|
Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.
The top and bottom lines aren't that critical for Inovio right now. It's all about the pipeline -- and the biotech's cash position.
The Plymouth Meeting, Pennsylvania-based company said it had a loss of 40 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.
BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.
Inovio's (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q3. However, lack of an approved product in the company's portfolio is a dampener.
The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
Jim Cramer rattles off his take on caller favorite stocks, including these two energy players that could be competing for business.